Fay Lin
@faylinphd.bsky.social
56 followers 32 following 27 posts
Senior Technology Editor @ GEN Writing about AI x Bio ✉️ [email protected]
Posts Media Videos Starter Packs
faylinphd.bsky.social
David Baker's Nobel Prize-winning lab has now designed a molecular on/off switch to control the speed of protein binding, supporting safer medicines that quell harmful side effects and activate drugs on cue, and sensitive biosensors for SARS-CoV-2 testing!

www.genengnews.com/topics/artif...
AI-Designed Protein Switches Control Drugs with Speed
David Baker’s Nobel Prize-winning lab has designed protein on/off switches as a tool for tunable cancer immunotherapies and biosensors.
www.genengnews.com
faylinphd.bsky.social
BindCraft is now published in @nature.com!

The open-source pipeline for de novo protein binder design achieves significantly improved success rates with nanomolar affinity and therapeutic potential from gene editing to allergens.

Read more at GEN:
www.genengnews.com/topics/artif...
BindCraft AI Model Achieves One-Shot Functional Protein Design
The open-source pipeline designs proteins with improved success rates for therapeutic targets, including gene editing proteins and allergens.
www.genengnews.com
faylinphd.bsky.social
Given the high uptake for a “Cas9 look-alike,” the team is inspired to expand toward new territories, including base editors, prime editors, large insertion techniques, and more to demonstrate the generalizability of its protein design platform. 4/4
faylinphd.bsky.social
Since OpenCRISPR-1's open source release in April 2024, tens of thousands of academic and industry researchers have accessed the sequence across a variety of verticals, from developing drought-resistant crops to drug discovery. 3/
faylinphd.bsky.social
Despite being hundreds of mutations away from any known natural protein. Profluent's LLM generated CRISPR proteins show improved activity, specificity, and immunogenicity relative to naturally occurring gene editors. 2/
faylinphd.bsky.social
David Baker's Nobel Prize-winning lab has now designed binders to "undruggable" disordered proteins, unlocking therapeutic access to over 50% of the human proteome!

‪@uwproteindesign.bsky.social‬

Read more at GEN:
tinyurl.com/4fw6wvkm
Undruggable No More: AI Hits Disordered Proteins, Unlocks Therapy Targets
David Baker’s lab has successfully designed binders to disordered proteins, expanding therapeutic access to over 50% of the human proteome.
tinyurl.com
faylinphd.bsky.social
As a baseline, competitors will initially go head-to-head with Arc’s first virtual cell model, STATE, which is designed to predict how various stem cells, cancer cells, and immune cells respond to drugs, cytokines, or genetic perturbations. 3/3
faylinphd.bsky.social
The initiative is a step toward virtual cell benchmarking and acceleration, and follows in the footsteps of the CASP competition, the biannual experiment that assesses the latest state-of-the-art models in protein structure prediction, which enabled Nobel Prize-winning, AlphaFold. 2/
faylinphd.bsky.social
Xaira Therapeutics has released the largest publicly available Perturb-seq dataset to train the AI-powered virtual cell for drug discovery!

The work is described in Xaira's first preprint, capping a year after the company's $1 billion launch.

www.genengnews.com/topics/artif...
Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual Cell
The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.
www.genengnews.com
faylinphd.bsky.social
In collaboration with @recursionpharma.bsky.social, the work was led by Gabriele Corso @gcorso.bsky.social, Saro Passaro, and Jeremy Wohlwend from the lab of Regina Barzilay at @mit.edu!
faylinphd.bsky.social
Boltz-2 now predicts molecular binding affinity at newfound speed and accuracy - and it's open source!

The permissive MIT license allows commercial drug developers to apply proprietary data and offers an advance over the structure prediction capabilities of AlphaFold 3.

tinyurl.com/37c96c6y
Boltz-2 Released to Democratize AI Molecular Modeling for Drug Discovery
The MIT model predicts molecular binding affinity at newfound speed and accuracy, offering a powerful tool for commercial drug discovery.
www.genengnews.com
faylinphd.bsky.social
AI hype or reality - can we design antibodies from scratch (de novo)?

In my latest for GEN, I unpack where de novo design is today and how arguments over terminology have clouded the industry’s shared mission of bringing better therapeutics to the clinic faster.

tinyurl.com/4uamc8c5
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox
Debates over AI antibody design terminology have clouded the industry’s shared mission of bringing better therapeutics to the clinic faster.
tinyurl.com
Reposted by Fay Lin
kevinadavies.bsky.social
Excellent story from @faylinphd.bsky.social on the hot news from #ASGCT2025@kiranmusunuru.bsky.social and colleagues tailor the world’s first bespoke gene editor to treat KJ, an infant with an ultra-rare genetic disease, heralding a new era in precision med.
www.genengnews.com/topics/genom...
faylinphd.bsky.social
BREAKING NEWS: World’s first patient treated with personalized CRISPR therapy!

Born with a severe metabolic disease with a 50% mortality rate, an infant has improved after receiving an individualized gene editing therapy, a glimpse of a new era in genomic precision medicine.

tinyurl.com/m52udxht
ASGCT 2025: World’s First Patient Treated with Personalized CRISPR Therapy
Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows improvement from a rare metabolic disease.
www.genengnews.com
faylinphd.bsky.social
A "ChatGPT prompter" for interrogating single-cell transcriptomics, TranscriptFormer probes cellular biology across organisms, with predictive capabilities for disease state classification and tissue context, and generative tasks, such as inferring cell type-specific transcription factors. 2/2